

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<b>Licensee</b>  1. Ivinson Memorial Hospital  2. 255 North 30th Street Laramie, WY 82072-5195		In accordance with letter dated March 02, 2022.	4. Expiration Date: June 30, 2034
		3. License No.: 49-15978-01 is amended in its entirety to read as follows:	5. Docket No.: 030-10133 Reference No.:
6. Byproduct, source, and/or special nuclear material  A. Any byproduct material permitted by 10 CFR 35.100  B. Any byproduct material permitted by 10 CFR 35.200  C. Any byproduct material permitted by 10 CFR 35.300	7. Chemical and/or physical form  A. Any  B. Any  C. Any	8. Maximum amount that licensee may possess at any one time under this license  A. As Needed  B. As Needed  C. 1 curie total	9. Authorized use  A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.  B. For use in imaging and localization studies permitted by 10 CFR 35.200.  C. For any use permitted by 10 CFR 35.300.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 49-15978-01

Docket or Reference No.:  
030-10133

Amendment No. 31

- |   |  |  |   |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form   | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use   |
| D. Any byproduct material permitted in 10 CFR 35.400  | D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Best Medical International, Inc. (Formerly Best Industries, Inc.), Model 2300 Series; Core Oncology, Inc. (Formerly Mills Biopharmaceuticals, LLC.), Model I-125 SL and I-125 SH; International Brachytherapy, Inc./International Brachytherapy SA., Model OptiSeed103 Model 1032P or InterSource Model 1231L implant seeds; IsoAid, L.L.C., Model IAI-125A (Advantage™ I-125) or IAPd-103A (Advantage™ Pd-103); Medi-Physics, Inc. d/b/a GE Healthcare, Model 6711 (OncoSeed™); Medi-Physics, Inc./Amersham Health, Model 6733 (EchoSeed™); North American Scientific, Inc., Model MED3631 or MED3633; Theragenics Corporation, Model I-Seed Model I25.S06 or TheraSeed Model 200) | D. 5 curies total  | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
- 

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 49-15978-01

Amendment No. 31

Docket or Reference No.:  
030-10133**CONDITIONS**

10. Licensed material may be used or stored at the licensee's facilities located at 255 North 30th Street, Laramie, Wyoming 82072-5195.
11. The Radiation Safety Officer (RSO) for this license is Jeanne M. Hennemann, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u>   |
|---|---|
| Bruce A. Berkowitz, M.D.                  | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| John R. Bodenhamer, M.D.                  | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| Joseph M. Carabetta, M.D.                 | 35.100; 35.200  |
| Kenneth K. Cicuto, M.D.                   | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| Jamie S. Colonnello, M.D.                 | 35.100; 35.200; Oral administration of sodium iodide I-131 less than or equal to 33 millicuries |
| Nicholas J. Constantine, M.D.             | 35.100; 35.200  |
| Winfield M. Craven, M.D.                  | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| Jason P. Doye, M.D.                       | 35.100; 35.200  |
| Thomas R. Dunphy, M.D.                    | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| Gabriel Edwards, M.D.                     | 35.100; 35.200  |
| Michael J. Geraghty                       | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |
| Deborah Z. Gunderson, M.D.                | 35.100; 35.200; 35.300  |
| Amy S. Hayes, M.D.                        | 35.100; 35.200; Oral administration of sodium iodide I-131                                      |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 49-15978-01

Docket or Reference No.:  
030-10133

Amendment No. 31

Authorized User (M.D., D.O., etc.)

Jeanne M. Hennemann, M.D.

Sarah Jess, M.D.

Alistair Jordan, D.O.

Karl E. Magsamen, M.D.

Justin Monroe, M.D.

Richard J. Pacini, M.D.

Steven H. Peck, M.D.

John D. Purviance, M.D.

John P. Stamato, M.D.

Nicholas Statkus, M.D.

Robert Lawrence Tobin, M.D.

Stanley W. Weinstein, M.D.

Jeffrey R. Weissmann, M.D.

Material and Use

35.100, 35.200; Oral administration of sodium iodide I-131

35.100; 35.200; Oral administration of sodium iodide I-131

35.100; 35.200

35.100; 35.200

35.100; 35.200; Oral administration of sodium iodide I-131

35.100; 35.200; Oral administration of sodium iodide I-131

35.100; 35.200; Oral administration of sodium iodide I-131

35.300; 35.400

35.300; 35.400

35.100; 35.200

35.300; 35.400

35.100; 35.200; Oral administration of sodium iodide I-131

35.100; 35.200; Oral administration of sodium iodide I-131

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 49-15978-01


Amendment No. 31

Docket or Reference No.:  
030-10133

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 28, 2019 (ML19044A266)

B. Letter dated March 2, 2022 (ML22187A266)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 11, 2022By: \_\_\_\_\_  
Michelle R. Simmons  
Region 4